Drug updated on 4/17/2024
| Dosage Form | Tablet (oral; 60 mg, 80 mg, 100 mg) |
| Drug Class | Thyroid hormone receptor-beta agonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| REZDIFFRA (resmetirom) Prescribing Information | 2024 | Madrigal Pharmaceuticals Inc., West Conshohocken, PA |
Randomized Controlled Trials
| Document Title | Sex Distribution | Year | Source |
|---|---|---|---|
| A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. | Data not availableSubjects F: null% M: null% | 2024 | New England Journal of Medicine |
| Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. | 1,143Subjects F: 57% M: 43% | 2023 | Nature Medicine |
Sex Distribution:
Year:
2024
Source:New England Journal of Medicine
Document Title
Sex Distribution:
F:57%
M:43%
1143Subjects
Year:
2023
Source:Nature Medicine